Bristol Myers pauses Zola-Cel review to assess clinical data
Bristol Myers spokesperson said the company implemented a voluntary pause to review clinical data across its Zola-Cel program.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.